Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04957992 · ClinicalTrials.gov registry record · NA
BIG Study (Brain, Immune, and Gut Health Evaluation of Infants/Young Children Fed Infant Formula, and Later Supplemental Toddler Nutrition, With 5 Specific HMOs)
A NA study, sponsored by Abbott Nutrition.
- Completed
- Registry status
- NA
- Development phase
- 607
- Enrollment target
NCT04957992: Completed NA study, sponsored by Abbott Nutrition.
NCT04957992 is a NA study that has completed, run by Abbott Nutrition. The registered enrollment target is 607 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04957992, a NA study, has completed, sponsored by Abbott Nutrition.
- COMPLETED
- Registry status
- NA
- Development phase
- 607 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the growth and development outcomes of infants fed a new infant formula and toddler drink through 24 months of age.
Primary Outcome
weight for age z-score
Interventions
- OTHER Experimental Infant Formula
- OTHER Control Infant Formula
- OTHER Control Toddler Drink
- OTHER Experimental Toddler Drink
- OTHER Human Milk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 607 participants |
| Start Date | 2021-07-21 |
| Est. Completion | 2025-05-12 |
| Phase | NA |
What the finished NCT04957992 record still lists
NCT04957992 is an interventional study that assigns participants to a tested intervention. The registered 607 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 5 interventions - of which Experimental Infant Formula is the first listed.
NCT04957992 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04957992 about?
NCT04957992 is a clinical study titled "BIG Study (Brain, Immune, and Gut Health Evaluation of Infants/Young Children Fed Infant Formula, and Later Supplemental Toddler Nutrition, With 5 Specific HMOs)". The purpose of this study is to evaluate the growth and development outcomes of infants fed a new infant formula and toddler drink through 24 months of age.
What is the current status of trial NCT04957992?
This trial is currently completed. It is a NA study. The enrollment target is 607 participants. The study started on 2021-07-21. Estimated completion is 2025-05-12.
What interventions are being tested in trial NCT04957992?
The interventions under investigation include: Experimental Infant Formula (OTHER), Control Infant Formula (OTHER), Control Toddler Drink (OTHER), Experimental Toddler Drink (OTHER), Human Milk (OTHER).
Who is sponsoring clinical trial NCT04957992?
This trial is sponsored by Abbott Nutrition, which has 89 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04957992's enrollment target sits among peer trials
607 162nd of 2000 higher than 1,839 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02064673 · 608 participants · Phase 3
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
- NCT06091202 · 608 participants · Phase 3
Tele-Collaborative Outreach to Rural Patients With Chronic Pain
- NCT06098144 · 608 participants · Phase 4
Smoking Cessation Program in the Construction Sector
- NCT02342444 · 606 participants · Phase 4
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI